Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects

NCT02042001 is registered in ClinicalTrials.gov with Azienda Ospedaliera San Gerardo di Monza as lead sponsor.

NCT NCT02042001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02042001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects
Lead sponsor
Azienda Ospedaliera San Gerardo di Monza
Phase
Phase 4
Overall status
Completed
Start date
July 1, 2015
Completion date
January 15, 2018
Enrollment
74 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

depression/anxiety, hiv-1 infection, impaired cognition, poor quality sleep, quality of life